JP2004534887A - 肥満症の治療のためのアリールボロネート官能基化ポリマー - Google Patents

肥満症の治療のためのアリールボロネート官能基化ポリマー Download PDF

Info

Publication number
JP2004534887A
JP2004534887A JP2003508952A JP2003508952A JP2004534887A JP 2004534887 A JP2004534887 A JP 2004534887A JP 2003508952 A JP2003508952 A JP 2003508952A JP 2003508952 A JP2003508952 A JP 2003508952A JP 2004534887 A JP2004534887 A JP 2004534887A
Authority
JP
Japan
Prior art keywords
group
substituted
polymer
ammonium
ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003508952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004534887A5 (https=
Inventor
ホームズ−ファーレイ，スティーブン，ランダル
サード マンデヴィル，ハリー，ダブリュ．，ザ
ダール，プラディープ，ケイ．
フーバル，チャド，コリ
リー，シンフア
ポロモスキャニック，スティーブン，シー．
Original Assignee
ジェンザイム コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェンザイム コーポレーション filed Critical ジェンザイム コーポレーション
Publication of JP2004534887A publication Critical patent/JP2004534887A/ja
Publication of JP2004534887A5 publication Critical patent/JP2004534887A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/42—Introducing metal atoms or metal-containing groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/44—Preparation of metal salts or ammonium salts
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0206—Polyalkylene(poly)amines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G79/00—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule
    • C08G79/08—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule a linkage containing boron

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003508952A 2001-06-29 2002-07-01 肥満症の治療のためのアリールボロネート官能基化ポリマー Pending JP2004534887A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30222101P 2001-06-29 2001-06-29
US35947302P 2002-02-22 2002-02-22
PCT/US2002/020947 WO2003002571A1 (en) 2001-06-29 2002-07-01 Aryl boronate functionalized polymers for treating obesity

Publications (2)

Publication Number Publication Date
JP2004534887A true JP2004534887A (ja) 2004-11-18
JP2004534887A5 JP2004534887A5 (https=) 2006-01-05

Family

ID=26972846

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003508952A Pending JP2004534887A (ja) 2001-06-29 2002-07-01 肥満症の治療のためのアリールボロネート官能基化ポリマー

Country Status (6)

Country Link
US (2) US7041280B2 (https=)
EP (1) EP1404686A1 (https=)
JP (1) JP2004534887A (https=)
AU (1) AU2002318470B2 (https=)
CA (1) CA2487857A1 (https=)
WO (1) WO2003002571A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003291567A1 (en) * 2002-11-19 2004-06-15 Genzyme Corporation Polymeric boronic acid derivatives as lipase inhibitors
GB2415193A (en) * 2004-06-19 2005-12-21 F2 Chemicals Ltd Fluorinated arylboronic acids
WO2010019718A2 (en) 2008-08-13 2010-02-18 California Institute Of Technology Carrier nanoparticles and related compositions, methods and systems
US20130157926A1 (en) 2010-06-18 2013-06-20 Johannes Franciscus Joseph Engbersen Boronated polymers
US9732101B2 (en) 2012-01-18 2017-08-15 Wisconsin Alumni Research Foundation Bioreversible boronates for delivery of molecules into cells
US9234048B2 (en) 2012-01-18 2016-01-12 Wisconsin Alumni Research Foundation Boronate-mediated delivery of molecules into cells
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
JP6914860B2 (ja) 2015-07-01 2021-08-04 カリフォルニア インスティチュート オブ テクノロジー カチオン性粘液酸ポリマー系デリバリーシステム
TR201703622A1 (tr) 2017-03-09 2018-09-21 Univ Yeditepe Obezi̇te tedavi̇si̇ i̇çi̇n bi̇r ürün
WO2019241327A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
EP3852768A4 (en) * 2018-09-20 2022-09-14 Glyscend, Inc. BORONIC ACID POLYMERS AND METHODS OF USE
WO2021055759A1 (en) 2019-09-20 2021-03-25 Glyscend, Inc. Substituted phenyl boronic acid containing polymers and methods of use

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7017227A (https=) * 1969-12-27 1971-06-29
US3923972A (en) * 1971-10-12 1975-12-02 Monsanto Co Method of lowering blood cholesterol level
US4211765A (en) * 1971-10-12 1980-07-08 Monsanto Company Method for controlling obesity
IT1052819B (it) * 1975-12-12 1981-07-20 Fargal Pharmasint Lab Biochim Preparato inibitore dell assorbimento dei lipidi a base di dietilamminoetildestrano
US4265879A (en) * 1977-09-13 1981-05-05 Monsanto Company Method for controlling blood triglycerides
US4302450A (en) * 1979-01-15 1981-11-24 Hoffmann-La Roche Inc. Polyether ionophores as antiobesity and hypotriglyceridemic agents
US4218443A (en) * 1979-01-15 1980-08-19 Hoffmann-La Roche Inc. Polyether ionophores as antiobesity and hypotriglyceridemic agents
US4432968A (en) * 1980-10-20 1984-02-21 The Dow Chemical Company Weight control with fat imbibing polymers
US4496722A (en) 1981-05-01 1985-01-29 The Children's Medical Center Corporation Reporter compounds
US4634722A (en) * 1981-05-20 1987-01-06 Syntex (U.S.A.) Inc. Copolymers and hydrogels: process and articles made thereof
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
US5200183A (en) * 1987-11-19 1993-04-06 Oklahoma Medical Research Foundation Recombinant bile salt activated lipases
GB8819224D0 (en) 1988-08-12 1988-09-14 Merck Patent Gmbh Process for preparation of rod-like compounds
US4959179A (en) * 1989-01-30 1990-09-25 Lever Brothers Company Stabilized enzymes liquid detergent composition containing lipase and protease
US5089163A (en) * 1989-01-30 1992-02-18 Lever Brothers Company, Division Of Conopco, Inc. Enzymatic liquid detergent composition
US5063210A (en) * 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US5484777A (en) * 1989-04-20 1996-01-16 Lange, Iii; Louis G. Pancreatic cholesterol esterase inhibitor
US5308766A (en) * 1989-08-29 1994-05-03 The Regents Of The University Of California Hydrolytic enzyme inhibitors/inactivators and methods for using same
CA2064793C (en) * 1989-08-29 2001-11-13 Edward A. Dennis Hydrolytic enzyme inhibitors and substrates and assays, methods and kits embodying same
DE3930663C1 (en) 1989-09-14 1990-11-15 Merck Patent Gmbh, 6100 Darmstadt, De Cross-coupling metal organic cpds. and e.g. halogen cpds. - includes using transition metal-palladium catalyst and opt. metal alcoholate
US5260310A (en) * 1990-02-26 1993-11-09 Hoffmann-La Roche Inc. Oxetanone compounds and pharmaceutical compositions containing them
EP0478050A1 (en) 1990-09-24 1992-04-01 Unilever N.V. Detergent composition
GB9024775D0 (en) 1990-11-14 1991-01-02 Axis Research Chemical compounds
US5137716A (en) * 1990-11-15 1992-08-11 Weisenfeld Michael S Method of reducing weight in mammals
IE914573A1 (en) 1991-01-17 1992-07-29 Ici Plc Boron compounds
SK120993A3 (en) 1991-04-30 1994-08-10 Procter & Gamble Liquid detergents with an aryl boronic acid
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
ZA929351B (en) * 1991-12-11 1993-06-04 Igen Inc Electrochemiluminescent label for DNA assays.
DE69328741T2 (de) * 1992-01-14 2000-09-07 Hisamitsu Pharmaceutical Co., Inc. Unvernetztes Anion-Austauscherharz und diesen enthaltende pharmazeutische Zusammensetzung
CH683522A5 (de) 1992-03-13 1994-03-31 Hoffmann La Roche Verfahren zur Herstellung von Diarylen.
JP2667351B2 (ja) * 1992-03-24 1997-10-27 麒麟麦酒株式会社 食餌脂質消化吸収阻害剤および飲食品
ATE130193T1 (de) * 1992-03-28 1995-12-15 Hoechst Ag Arzneimittel aus polyhydroxymethylenderivaten, verfahren zu deren herstellung und verwendung.
CA2096496A1 (en) 1992-05-29 1993-11-30 Bradley C. Pearce Acyclic tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia
US5290817A (en) 1992-06-09 1994-03-01 The Du Pont Merck Pharmaceutical Co. Substituted 1-benzylindanes and their use as inhibitors of phospholipase A2
WO1994014803A1 (en) 1992-12-21 1994-07-07 Zeneca Limited Quinuclidine derivatives as squalene synthase inhibitors
GB2276162A (en) 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benazilide derivatives
US5487888A (en) 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5624963A (en) 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5618530A (en) 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5703188A (en) 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5900475A (en) 1994-06-10 1999-05-04 Geltex Pharmaceuticals, Inc. Hydrophobic sequestrant for cholesterol depletion
JP3894949B2 (ja) 1993-06-30 2007-03-22 ザ、ウェルカム、ファンデーション、リミテッド 抗アテローム性動脈硬化症ジアリール化合物
US5840677A (en) 1993-07-09 1998-11-24 Novo Nordisk A/S Boronic acid or borinic acid derivatives as enzyme stabilizers
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5569452A (en) * 1993-08-31 1996-10-29 Tsrl, Inc. Pharmaceutical formulation having enhanced bile acid binding affinity
WO1995011243A1 (en) 1993-10-19 1995-04-27 Smithkline Beecham Plc Benzanilide derivatives as 5ht-1d receptor antagonists
US5414068A (en) * 1994-01-24 1995-05-09 Rohm And Haas Company Crosslinked anion exchange particles and method for producing the particles
US5726343A (en) 1994-01-27 1998-03-10 Novartis Corporation Process for the preparation of arylacetic ester derivatives via palladium-catalyzed cross coupling reaction
US5631364A (en) 1994-03-31 1997-05-20 Axis Biochemicals Asa Labelled boronic acid derivatives
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5474993A (en) * 1994-06-14 1995-12-12 Sterling Winthrop, Inc. Lactam inhibitors of cholesterol esterase
SI9400289A (en) 1994-07-13 1996-02-29 Ponikvar Jadranka Buturovic A method for preventing blood coagulation in a haemodialysis circuit or haemodialysis analogy procedure in the extra-body circuit.
JPH0859458A (ja) * 1994-08-25 1996-03-05 Zeria Pharmaceut Co Ltd インダン誘導体を含有する高脂血症治療剤
EP0796252A4 (en) 1994-12-09 1998-02-04 Smithkline Beecham Corp BICYCLIC FIBRINOGEN ANTAGONISTS
EP0802968A1 (en) 1995-01-09 1997-10-29 Novo Nordisk A/S Stabilization of liquid enzyme compositions
WO1996030333A1 (en) 1995-03-27 1996-10-03 Smithkline Beecham Plc Bicyclic amine derivatives and their use as anti-psychotic agents
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
CN1103810C (zh) 1995-06-13 2003-03-26 诺沃奇梅兹有限公司 含苯基硼酸衍生物酶稳定剂的液冻组合物
US5631371A (en) 1995-11-22 1997-05-20 Bayer Corporation Method for the preparation of substituted 3-(phenylimino)-3H-phenothiazines and phenoxazines
GB9603137D0 (en) 1996-02-15 1996-04-17 Merck Sharp & Dohme Therapeutic agents
US6034129A (en) 1996-06-24 2000-03-07 Geltex Pharmaceuticals, Inc. Ionic polymers as anti-infective agents
WO1998022820A1 (en) 1996-11-21 1998-05-28 Lawrence Livermore National Laboratory Detection of biological molecules using boronate-based chemical amplification and optical sensors
US6203785B1 (en) 1996-12-30 2001-03-20 Geltex Pharmaceuticals, Inc. Poly(diallylamine)-based bile acid sequestrants
US5925379A (en) 1997-03-27 1999-07-20 Geltex Pharmaceuticals, Inc. Interpenetrating polymer networks for sequestration of bile acids
US6159979A (en) 1997-04-18 2000-12-12 Smithkline Beecham P.L.C. Bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity
WO1998056392A1 (en) 1997-06-13 1998-12-17 Northwestern University INHIBITORS OF β-LACTAMASES AND USES THEREFOR
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
JP2002510328A (ja) 1997-07-25 2002-04-02 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体アンタゴニスト
US5900233A (en) * 1997-10-16 1999-05-04 Day; Charles E. Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in treating irritable bowel syndrome
CO5011067A1 (es) 1997-11-03 2001-02-28 Novartis Ag Derivados de bifenilo como productos farmaceuticos, su pre- paracion y composiciones farmaceuticas que los contienen
US5985938A (en) 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6299868B1 (en) * 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US6264937B1 (en) 1998-01-09 2001-07-24 Geltex Pharmaceuticals, Inc. Fat-binding polymers
DE69903615T2 (de) 1998-03-18 2003-06-26 Ciba Speciality Chemicals Holding Inc., Basel Kupplungsreaktionen mit palladiumkatalysatoren
US6525099B1 (en) 1998-07-31 2003-02-25 Eli Lilly And Company N-substituted sulfonamide derivatives
PT1105123E (pt) * 1998-08-14 2004-08-31 Hoffmann La Roche Composicoes farmaceuticas contendo inibidores da lipase e quitosano
TR200100471T2 (tr) * 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri içeren farmasötik bileşimler
WO2000014083A1 (en) 1998-09-09 2000-03-16 Inflazyme Pharmaceuticals Ltd. SUBSTITUTED η-PHENYL-Δ-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
DE19857765A1 (de) 1998-12-15 2000-06-21 Clariant Gmbh Verfahren zur Herstellung von para-Oxadiazolyl-phenyl-boronsäuren
AU3124300A (en) 1998-12-16 2000-07-03 Northwestern University Inhibitors of beta-lactamases and uses therefor
JP4865129B2 (ja) 1999-01-13 2012-02-01 ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク タンパク質キナーゼ阻害剤を設計するための新規の方法
DZ3265A1 (fr) 1999-04-14 2000-10-19 Pacific Corp Derives de 4,5-diaryl-3(2h)-furanone comme inhibiteurs de cyclo-oxygenase-2
JP4507294B2 (ja) 1999-05-27 2010-07-21 チッソ株式会社 ビアリール誘導体の製造方法
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6858592B2 (en) * 2001-06-29 2005-02-22 Genzyme Corporation Aryl boronic acids for treating obesity
US7045652B2 (en) * 2002-07-03 2006-05-16 Pfizer Inc Processes for preparing substituted aryl boronic acids

Also Published As

Publication number Publication date
AU2002318470B2 (en) 2005-09-08
US7041280B2 (en) 2006-05-09
EP1404686A1 (en) 2004-04-07
WO2003002571A1 (en) 2003-01-09
US20030059399A1 (en) 2003-03-27
CA2487857A1 (en) 2003-01-09
US20060128663A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
RU2146266C1 (ru) Способ секвестрации солей желчных кислот из организма, терапевтическая и полимерные композиции для осуществления этого способа
EP1404685B1 (en) Aryl boronic acids for treating obesity
US6225355B1 (en) Process for removing bile salts from a patient and alkylated compositions therefor
CA2303447C (en) Cationic polymers as toxin-binding agents
AU2002316499A1 (en) Aryl Boronic Acids For Treating Obesity
AU724507B2 (en) Poly(diallylamine)-based bile acid sequestrants
JP2004534887A (ja) 肥満症の治療のためのアリールボロネート官能基化ポリマー
US20060134062A1 (en) Polymeric boronic acid derivatives as lipase inhibitors
AU2002318470A1 (en) Aryl boronate functionalized polymers for treating obesity
JP4465193B2 (ja) リン酸塩輸送インヒビター
JP2005502615A (ja) 脂肪結合ポリマー
AU774636B2 (en) Fat-binding polymers, optionally combined with lipase inhibitors
KR100773625B1 (ko) 지방-결합성 중합체
HK1065046B (en) Aryl boronic acids for treating obesity
MXPA00004329A (en) Unsubstituted polydiallylamine for treating hypercholesterolemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050629

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20080731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080812

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090129